Company Cardio Diagnostics Holdings, Inc.

Equities

CDIO

US14159C1036

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for Cardio Diagnostics Holdings, Inc.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Real-time Estimate Cboe BZX Other stock markets 04:00:12 2024-05-10 pm EDT			5-day change	1st Jan Change
0.896 ^USD	+23.15%		+21.27%	-62.65%

Apr. 29	Cardio Diagnostics Holdings, Inc. Announces Publication of Study Showing That Its PrecisionCHD Test Could Save Health Insurers over $113 Million Annually	CI
Apr. 19	Sector Update: Health Care Stocks Advance Late Afternoon	MT

Cardio Diagnostics Holdings, Inc. is an artificial intelligence-powered precision cardiovascular medicine company. The Company develops and commercializes a series of products for various types of cardiovascular disease and associated co-morbidities, including coronary heart disease (CHD), stroke, heart failure and diabetes, by leveraging its artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine. Its first product, Epi+Gen CHD, is an epigenetics-based clinical blood test capable of assessing near-term (three-year) risk for CHD, and its second product, PrecisionCHD, is an epigenetics-based clinical blood test for the detection of CHD. CardioInnovate360 is a research use only (RUO) solution to support the discovery, development and validation of biopharmaceuticals for the assessment and management of cardiovascular diseases. HeartRisk is a cardiovascular risk intelligence platform that combines insights from anonymized and aggregated clinical cardiovascular data.

Number of employees: 8

USD in Million	2022	Weight	2023	Weight	Delta
Artificial Intelligence-driven DNA Biomarker Testing Technology 100.0 %	0	100.0 %	0	100.0 %	+1,696.32%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	0	100.0 %	0	100.0 %	+1,696.32%

Managers	Title	Age	Since
Meeshanthini Dogan CEO	Chief Executive Officer	35	22-10-24
Elisa Luqman DFI	Director of Finance/CFO	59	22-10-24
Timur Dogan CTO	Chief Tech/Sci/R&D Officer	36	22-10-24
Robert Philibert CTO	Chief Tech/Sci/R&D Officer	63	22-10-24
Khullani Abdullahi IRO	Public Communications Contact	41	22-10-24
Gene Mannheimer IRC	Investor Relations Contact	-	-

Members of the board	Title	Age	Since
Warren Hosseinion CHM	Chairman	52	22-10-24
Oded Levy BRD	Director/Board Member	63	22-10-24
Paul Burton BRD	Director/Board Member	-	Dec. 20
Stanley Lau BRD	Director/Board Member	68	22-10-24
Meeshanthini Dogan CEO	Chief Executive Officer	35	22-10-24
Robert Philibert CTO	Chief Tech/Sci/R&D Officer	63	22-10-24
James Intrater BRD	Director/Board Member	60	22-10-24

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	21,591,119	17,758,070 ( 82.25 %)	0	82.25 %

Name	Equities	%	Valuation
Robert Philibert 8.032 %	1,649,792	8.032 %	2 M $
Meeshanthini Dogan 7.724 %	1,586,464	7.724 %	2 M $
BlackRock Fund Advisors 5.195 %	1,067,062	5.195 %	2 M $
BlackRock Institutional Trust Co. NA 5.195 %	1,067,062	5.195 %	2 M $
Vanguard Group, Inc. (Subfiler) 1.130 %	232,139	1.130 %	329 637 $
Geode Capital Management LLC 0.6738 %	138,411	0.6738 %	196 544 $
Timur Dogan 0.6248 %	128,345	0.6248 %	182 250 $
Warren Hosseinion 0.5650 %	116,053	0.5650 %	164 795 $
Stanley Lau 0.4456 %	91,522	0.4456 %	129 961 $
Brandon Sim 0.3057 %	62,793	0.3057 %	89 166 $

Name	Equities	%	Valuation
Walleye Capital LLC -	234,907	-	24 900 $
EHP Funds, Inc. -	228,952	-	24 269 $
EdgeHill Partners -	228,952	-	24 269 $
Saba Capital Management LP -	199,839	-	21 183 $
Walleye Trading LLC -	132,265	-	14 020 $
Clear Street LLC -	83,042	-	8 802 $
Context Capital Management LLC -	81,500	-	8 639 $
D.E. Shaw & Co., Inc. -	74,822	-	7 931 $
Boothbay Fund Management LLC -	60,540	-	6 417 $
RiverNorth Capital Management LLC -	39,830	-	4 222 $

Cardio Diagnostics Holdings, Inc.

311 West Superior Street Suite 444

60654, Chicago

http://www.cardiodiagnosticsinc.com

address Cardio Diagnostics Holdings, Inc.(CDIO)

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.7276 USD

Average target price

4.675 USD

Spread / Average Target

+542.57%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
CARDIO DIAGNOSTICS HOLDINGS, INC.	-70.78%	15.71M
VERTEX PHARMACEUTICALS INCORPORATED	+2.97%	108B
REGENERON PHARMACEUTICALS, INC.	+10.21%	104B
ARGENX SE	+2.85%	22.33B
BIONTECH SE	-12.77%	22.19B
GENMAB A/S	-7.05%	18.69B
WUXI APPTEC CO., LTD.	-37.64%	17.74B
BEIGENE, LTD.	-6.50%	17.64B
NEUROCRINE BIOSCIENCES, INC.	+6.00%	14.05B
SAREPTA THERAPEUTICS, INC.	+37.20%	12.51B

Bio Therapeutic Drugs